Drugs / Balaglitazone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00515632 | Jul 2007 → Jul 2009 | type 2 diabetes mellitus | Rheoscience A/S | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Balaglitazone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00515632 ↗ |
| Known as | Balaglitazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103991 ↗ |
| Known as | DRF-2593 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103991 ↗ |
| Known as | NN-2344 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103991 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor gamma partial agonist” CHEMBL2103991 ↗1“PPARγ partial agonist balaglitazone” PMID 21328517 ↗ May 2011 |
| Modality | Small molecule | “Balaglitazone is a thiazolidinedione derivative” NCT00515632 ↗ |
| Route | Oral | “orally taken once daily” NCT00515632 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma partial agonist” CHEMBL2103991 ↗ |